Table 3.

New treatment modalities based on targeted therapies in metastatic pancreatic cancer

Treatment modality	Mechanism of action	Target
Immunotherapy	Check point inhibitors	CTLA4
	Adoptive cell therapy	T-cells
Epigenetics	Histone acetylation	Histones
Stromal extracellular matrix	Hyaluronidase	Hyaluronan
Tumor suppressor genes regulation	miRNA inhibitors	TP53-SMAD4- CDKN2A
	Anti-PARP	BRCA1-BRCA2

CTLA4: Cytotoxic T-lymphocyte-associated antigen 4; TP53-SMAD4- CDKN2A: Tumor protein p53 - cyclin-dependent kinase inhibitor 2A; BRCA: Breast cancer; PARP: PolyADP ribose polymerase.